Christopher A Klebanoff
Overview
Explore the profile of Christopher A Klebanoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
12838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avutu V, Algazaq J, Seier K, Desir-Camille R, Qin L, Babatunde O, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39993596
Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are...
2.
Kwok D, Stevers N, Etxeberria I, Nejo T, Colton Cove M, Chen L, et al.
Nature
. 2025 Feb;
639(8054):463-473.
PMID: 39972144
T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens. However, their efficacy is limited in tumours with few somatic mutations and substantial...
3.
Ma J, Ayres C, Brambley C, Chandran S, Rosales T, Perera W, et al.
Nat Commun
. 2025 Jan;
16(1):849.
PMID: 39833157
The inherent antigen cross-reactivity of the T cell receptor (TCR) is balanced by high specificity. Surprisingly, TCR specificity often manifests in ways not easily interpreted from static structures. Here we...
4.
James S, Chen S, Ng B, Fischman J, Jahn L, Boardman A, et al.
Nat Biomed Eng
. 2024 Dec;
8(12):1592-1614.
PMID: 39715901
Resistance to chimaeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms, most notably antigen loss and tumour-induced immune suppression. It has been suggested that T cells expressing multiple...
5.
Gormally M, Chen M, Noronha A, Panageas K, Reynolds M, Kohlasch K, et al.
JAMA Oncol
. 2024 Nov;
11(1):74-76.
PMID: 39602136
No abstract available.
6.
Lupo K, Panjwani M, Shahid S, Sottile R, Lawry C, Kolk G, et al.
bioRxiv
. 2024 Aug;
PMID: 39211122
Engineered T and NK cell therapies have widely been used to treat hematologic malignancies and solid tumors, with promising clinical results. Current chimeric antigen receptor (CAR) T cell therapeutics have,...
7.
Ma J, Ayres C, Brambley C, Chandran S, Rosales T, Corcelli S, et al.
Res Sq
. 2024 Jun;
PMID: 38854019
The inherent cross-reactivity of the T cell receptor (TCR) is balanced by high specificity, which often manifests in confounding ways not easily interpretable from static structures. We show here that...
8.
Yi F, Cohen T, Zimmerman N, Dundar F, Zumbo P, Eltilib R, et al.
bioRxiv
. 2024 Mar;
PMID: 38464085
Chimeric antigen receptor (CAR)-engineered T and NK cells can cause durable remission of B-cell malignancies; however, limited persistence restrains the full potential of these therapies in many patients. The FAS...
9.
Kwok D, Stevers N, Nejo T, Chen L, Etxeberria I, Jung J, et al.
bioRxiv
. 2023 Oct;
PMID: 37904942
T-cell-mediated immunotherapies are limited by the extent to which cancer-specific antigens are homogenously expressed throughout a tumor. We reasoned that recurrent splicing aberrations in cancer represent a potential source of...
10.
Klebanoff C, Chandran S, Baker B, Quezada S, Ribas A
Nat Rev Drug Discov
. 2023 Oct;
22(12):996-1017.
PMID: 37891435
The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects, amplifies and coordinates cellular immune responses to epitopes derived from cell surface and intracellular proteins. Thus,...